State Street
PYXS icon

State Street’s Pyxis Oncology PYXS Stock Holding History

State Street’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$363K Buy
248,837
+7,200
+3% +$10.9K ﹤0.01% 3732
2025
Q4 		$278K Buy
241,637
+39,582
+20% +$140K ﹤0.01% 3817
2025
Q3 		$449K Buy
202,055
+16,000
+9% +$23K ﹤0.01% 3686
2025
Q2 		$205K Sell
186,055
-746,143
-80% -$841K ﹤0.01% 3828
2025
Q1 		$913K Sell
932,198
-11,970
-1% -$16K ﹤0.01% 3449
2024
Q4 		$1.47M Sell
944,168
-7,083
-0.7% -$20.4K ﹤0.01% 3401
2024
Q3 		$3.49M Buy
951,251
+208,344
+28% +$729K ﹤0.01% 3114
2024
Q2 		$2.46M Buy
742,907
+633,552
+579% +$2.66M ﹤0.01% 3239
2024
Q1 		$466K Buy
109,355
+26,300
+32% +$111K ﹤0.01% 3666
2023
Q4 		$149K Hold
83,055
– – ﹤0.01% 3955
2023
Q3 		$165K Buy
83,055
+9,366
+13% +$21.7K ﹤0.01% 3987
2023
Q2 		$189K Buy
73,689
+11,400
+18% +$36.2K ﹤0.01% 4024
2023
Q1 		$250K Hold
62,289
– – ﹤0.01% 3984
2022
Q4 		$83.5K Buy
62,289
+31,300
+101% +$47K ﹤0.01% 4424
2022
Q3 		$61K Hold
30,989
– – ﹤0.01% 4614
2022
Q2 		$74K Sell
30,989
-113,806
-79% -$303K ﹤0.01% 4629
2022
Q1 		$585K Buy
144,795
+51,920
+56% +$380K ﹤0.01% 3977
2021
Q4 		$1.02M Buy
+92,875
New +$1.06M ﹤0.01% 3814

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street's PYXS Position: Q1 2026 in Review

State Street increased its Pyxis Oncology (PYXS) stake by 3% in Q1 2026, buying an estimated $10.9K and bringing the position to 248,837 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #3732.

State Street first reported a position in PYXS in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.49M in Q3 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • State Street held 248,837 shares of Pyxis Oncology worth $363K as of Q1 2026.
  • State Street bought 7,200 Pyxis Oncology shares in Q1 2026, an estimated $10.9K.
  • Pyxis Oncology made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3732 holding.
  • State Street first reported a position in Pyxis Oncology in Q4 2021 and has held it in 18 quarters since.
  • State Street's Pyxis Oncology position peaked at $3.49M in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.